The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

The U.S. Food and Drug Administration’s (or FDA) approval for Keytruda on October 2, 2015, to treat patients suffering with advanced non-small cell lung cancer (or NSCLC) is considered to be a major ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent cliff ...